{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:19:24Z","timestamp":1783441164093,"version":"3.54.6"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018840","name":"Bruce J. Anderson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018840","id-type":"DOI","asserted-by":"publisher"}]},{"name":"McLean Private Donors Psychiatry Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Depression is a therapeutic challenge with bipolar disorder (BD) patients and remains a major contributor to disability, comorbidity, and premature mortality. The efficacy and safety of antidepressants (ADs) for this indication remain particularly controversial, and optimally safe and effective treatment of bipolar (BP) depression remains uncertain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>We summarized selected research findings on the treatment of depression in BD aimed at supporting practical guidelines for clinical treatment involving ADs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Growing research evidence indicates that ADs are probably effective in BP depression and possibly not less than in major depressive disorder. Tolerability of antidepressant (AD) treatment is greater with type II BD (BD-2) than with type I (BD-1), particularly when ADs are combined with a mood stabilizer or antipsychotic. For BP depression, preferred ADs are serotonin-reuptake inhibitors and bupropion given in moderate doses for limited times.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Optimal treatment of depression requires further investigation, particularly for long-term maintenance. Nevertheless, treatment for acute depressive episodes can usefully and safely include some ADs in moderate doses for limited duration, best combined with lithium, some anticonvulsants, or certain atypical antipsychotics, and more safely with BD-2 than BD-1 with close clinical supervision.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijnp\/pyaf013","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:09:52Z","timestamp":1739894992000},"source":"Crossref","is-referenced-by-count":9,"title":["Antidepressants in the treatment of bipolar depression: commentary"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-3336","authenticated-orcid":false,"given":"Gustavo H","family":"V\u00e1zquez","sequence":"first","affiliation":[{"name":"International Consortium for Mood & Psychotic Disorders Research, Mailman Research Center, McLean Hospital , Belmont, MA,","place":["United States"]},{"name":"Department of Psychiatry, School of Medicine, Queen\u2019s University , Kingston, Ontario,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross J","family":"Baldessarini","sequence":"additional","affiliation":[{"name":"International Consortium for Mood & Psychotic Disorders Research, Mailman Research Center, McLean Hospital , Belmont, MA,","place":["United States"]},{"name":"Department of Psychiatry, Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"2025032308064777600_CIT0001","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40345-022-00268-2","article-title":"Differences between bipolar disorder types 1","volume":"10","author":"Tondo","year":"2022","journal-title":"Int J Bipolar Disord."},{"key":"2025032308064777600_CIT0002","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/HRP.0000000000000371","article-title":"Status of type II vs. type I bipolar disorder: systematic review with meta-analyses","volume":"31","author":"Hernandorena","year":"2023","journal-title":"Harv Rev Psychiatry."},{"key":"2025032308064777600_CIT0003","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jad.2015.02.011","article-title":"Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders","volume":"178","author":"Forte","year":"2015","journal-title":"J Affect Disord."},{"key":"2025032308064777600_CIT0004","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4614-3710-9","volume-title":"Chemotherapy in Psychiatry","author":"Baldessarini","year":"2013","edition":"3rd ed"},{"key":"2025032308064777600_CIT0005","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40345-019-0160-1","article-title":"Bipolar depression: a major unsolved challenge","volume":"8","author":"Baldessarini","year":"2020","journal-title":"Int J Bipolar Disord."},{"key":"2025032308064777600_CIT0006","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41380-018-0044-2","article-title":"Pharmacological treatment of adult bipolar disorder","volume":"24","author":"Baldessarini","year":"2019","journal-title":"Mol Psychiatry."},{"key":"2025032308064777600_CIT0007","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/acps.12343","article-title":"Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis","volume":"130","author":"Taylor","year":"2014","journal-title":"Acta Psychiatr Scand."},{"key":"2025032308064777600_CIT0008","doi-asserted-by":"publisher","first-page":"858","DOI":"10.2174\/1871527316666170728165648","article-title":"Potential novel treatments for bipolar depression: ketamine, fatty acids, anti-inflammatory agents, and probiotics","volume":"16","author":"V\u00e1zquez","year":"2017","journal-title":"CNS Neurol Disord Drug Targets."},{"key":"2025032308064777600_CIT0009","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jad.2020.03.030","article-title":"Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis","volume":"269","author":"Bahji","year":"2020","journal-title":"J Affect Disord."},{"key":"2025032308064777600_CIT0010","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1176\/appi.ps.59.10.1175","article-title":"Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence","volume":"59","author":"Baldessarini","year":"2008","journal-title":"Psychiatr Serv."},{"key":"2025032308064777600_CIT0011","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/acps.13519","article-title":"Mood stabilizers and risk of all-cause, natural, and suicide mortality in bipolar disorder: a nationwide cohort study","volume":"147","author":"Chen","year":"2023","journal-title":"Acta Psychiatr Scand."},{"key":"2025032308064777600_CIT0012","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1001\/jama.2023.18588","article-title":"Diagnosis and treatment of bipolar disorder: a review","volume":"330","author":"Nierenberg","year":"2023","journal-title":"JAMA."},{"key":"2025032308064777600_CIT0013","first-page":"229","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) for the management of patients with bipolar disorder","volume":"11","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"2025032308064777600_CIT0014","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1176\/appi.ajp.2013.13020185","article-title":"International Society for Bipolar Disorders (ISBD) task-force report on antidepressant use in bipolar disorders","volume":"170","author":"Pacchiarotti","year":"2013","journal-title":"Am J Psychiatry."},{"key":"2025032308064777600_CIT0015","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1055\/s-0030-1265198","article-title":"Comparison of antidepressant responses in patients with bipolar vs. unipolar depression: a meta-analytic review","volume":"44","author":"V\u00e1zquez","year":"2011","journal-title":"Pharmacopsychiatry."},{"key":"2025032308064777600_CIT0016","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1017\/s1461145713000023","article-title":"Overview of antidepressant treatment of bipolar depression","volume":"16","author":"V\u00e1zquez","year":"2014","journal-title":"Int J Neuropsychopharmacol."},{"key":"2025032308064777600_CIT0017","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/s2215-0366(23)00199-2","article-title":"Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis","volume":"10","author":"Yildiz","year":"2023","journal-title":"Lancet Psychiatry."},{"key":"2025032308064777600_CIT0018","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1192\/j.eurpsy.2024.25","article-title":"Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis","volume":"67","author":"Li","year":"2024","journal-title":"Eur Psychiatry."},{"key":"2025032308064777600_CIT0019","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/02698811241292946","article-title":"Responses to clinical treatment of bipolar vs. unipolar depressive episodes in women vs. men","volume":"39","author":"Baldessarini","year":"2025","journal-title":"J Psychopharmacol."},{"key":"2025032308064777600_CIT0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1600-0447.2008.01257.x","article-title":"Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks","volume":"118","author":"Ghaemi","year":"2010","journal-title":"Acta Psychiatr Scand."},{"key":"2025032308064777600_CIT0021","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1600-0447.2009.01514.x","article-title":"Mania associated with antidepressant treatment: comprehensive meta-analytic review","volume":"121","author":"Tondo","year":"2010","journal-title":"Acta Psychiatr Scand."},{"key":"2025032308064777600_CIT0022","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jad.2015.04.054","article-title":"Antidepressants worsen rapid-cycling course in bipolar depression\u2013a STEP-BD randomized clinical trial","volume":"184","author":"El-Mallakh","year":"2015","journal-title":"J Affect Disord."},{"key":"2025032308064777600_CIT0023","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1176\/appi.ajp.163.2.232","article-title":"Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers","volume":"163","author":"Leverich","year":"2006","journal-title":"Am J Psychiatry."},{"key":"2025032308064777600_CIT0024","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.euroneuro.2021.08.264","article-title":"Preventing new episodes of bipolar disorder in adults: systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Nestsiarovich","year":"2022","journal-title":"Eur Neuropsychopharmacol."},{"key":"2025032308064777600_CIT0025","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/10673220701551102","article-title":"Ecological studies of antidepressant treatment and suicidal risks","volume":"15","author":"Baldessarini","year":"2007","journal-title":"Harv Rev Psychiatry."},{"key":"2025032308064777600_CIT0026","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1503\/cmaj.081514","article-title":"Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies","volume":"180","author":"Barbui","year":"2009","journal-title":"CMAJ."},{"key":"2025032308064777600_CIT0027","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/HRP.0000000000000222","article-title":"Suicidal risk following hospital discharge: a review","volume":"27","author":"Forte","year":"2019","journal-title":"Harv Rev Psychiatry."},{"key":"2025032308064777600_CIT0028","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40345-024-00326-x","article-title":"Prevention of suicidal behavior with lithium treatment in patients with recurrent mood disorders","volume":"12","author":"Tondo","year":"2024","journal-title":"Int J Bipolar Disord."},{"key":"2025032308064777600_CIT0029","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jad.2022.11.039","article-title":"Comparison of bipolar disorder type II and major depressive disorder","volume":"323","author":"Miola","year":"2023","journal-title":"J Affect Disord."},{"key":"2025032308064777600_CIT0030","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/bdi.13378","article-title":"Multi-trial, aggregated, individual participant data mega-analysis of short-term antidepressant versus mood stabilizer monotherapy of bipolar type II major depressive episode","volume":"26","author":"Amsterdam","year":"2024","journal-title":"Bipolar Disord."},{"key":"2025032308064777600_CIT0031","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/acps.12023","article-title":"Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders","volume":"127","author":"Tondo","year":"2013","journal-title":"Acta Psychiatr Scand."},{"key":"2025032308064777600_CIT0032","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12888-021-03220-3","article-title":"Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis","volume":"21","author":"Kadakia","year":"2021","journal-title":"BMC Psychiatry."},{"key":"2025032308064777600_CIT0033","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.euroneuro.2019.02.003","article-title":"Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: a systematic review","volume":"29","author":"Pacchiarotti","year":"2019","journal-title":"Eur Neuropsychopharmacol."},{"key":"2025032308064777600_CIT0034","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1055\/s-0033-1363258","article-title":"Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium, and second-generation antipsychotics","volume":"47","author":"Selle","year":"2014","journal-title":"Pharmacopsychiatry."},{"key":"2025032308064777600_CIT0035","volume-title":"Practice Guideline for the Treatment of Patients with Bipolar Disorder","author":"Hirschfeld","year":"2010","edition":"2nd ed"},{"key":"2025032308064777600_CIT0036","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamapsychiatry.2020.2993","article-title":"Adjunctive psychotherapy for bipolar disorder: a systematic review and component network meta-analysis","volume":"78","author":"Miklowitz","year":"2021","journal-title":"JAMA Psychiatry."},{"key":"2025032308064777600_CIT0037","doi-asserted-by":"publisher","first-page":"105257","DOI":"10.1016\/j.neubiorev.2023.105257","article-title":"Lifestyle interventions for bipolar disorders: a systematic review and meta-analysis","volume":"152","author":"Simjanoski","year":"2023","journal-title":"Neurosci Biobehav Rev."}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaf013\/61940983\/pyaf013.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/3\/pyaf013\/61940983\/pyaf013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/3\/pyaf013\/61940983\/pyaf013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T12:58:14Z","timestamp":1742734694000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyaf013\/8020511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,20]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaf013","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,2,18]]},"article-number":"pyaf013"}}